• Publications
  • Influence
Nifedipine and flunarizine block amphetamine-induced behavioral stimulation in mice.
  • J. A. Grebb
  • Chemistry, Medicine
  • Life sciences
  • 30 June 1986
Sixteen calcium channel inhibitors (CCI's) were tested in a model utilizing amphetamine-induced behavioral stimulation in mice. Nifedipine, flunarizine and possibly PY 108-068 were effective inExpand
  • 61
  • 3
Electrophysiologic abnormalities in patients with eating disorders.
Abstract The authors present a pattern of electrophysiologic abnormalities from a computer-analyzed, electroencephalogram (EEG) and averaged evoked potential (AEP) test battery used in the assessmentExpand
  • 13
  • 2
Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY k 8644
The calcium channel agonist BAY k 8644 was used to investigate the role of the calcium ion (Ca2+) in epileptogenesis. Intracerebroventricular administration of the compound induced murine seizuresExpand
  • 60
  • 1
Evidence for down-regulation of 3H-nitrendipine recognition sites in mouse brain after long-term treatment with nifedipine or verapamil
Mice were fed powdered food which contained nifedipine, verapamil or diltiazem for 28 days. Long lasting treatment with nifedipine (0.28 mg/g b.w./day) or verapamil (0.27 mg/g b.w./day), but not withExpand
  • 66
Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment.
Alzheimer beta/A4 amyloid precursor protein (APP) has been suggested to play a central role in the pathogenesis of Alzheimer disease. We have measured the content of different species of APPExpand
  • 109
Differences between calcium channel inhibitors in their effects on phencyclidine-induced behavioral stimulation in mice
Sixteen calcium channel inhibitors (CCI's) were tested in a model utilizing phencyclidine (PCP)-induced behavioral stimulation in mice. There were marked differences in the effects of CCI's bothExpand
  • 26
A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia
Verapamil is a calcium channel inhibitor (CCI) of the papaverine subtype. This drug is in clinical use in the United States for the treatment of angina and cardiac arrhythmias. Verapamil has beenExpand
  • 44
Chronic Treatment of Rats with SCH‐23390 or Raclopride Does Not Affect the Concentrations of DARPP‐32 or Its mRNA in Dopamine‐Innervated Brain Regions
Abstract: DARPP‐32 (dopamine‐ and cyclic AMP‐regulated phosphoprotein, Mr= 32,000, as determined by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis) is a neuronal phosphoprotein that isExpand
  • 26
An analysis of synapsin II, a neuronal phosphoprotein, in postmortem brain tissue from alcoholic and neuropsychiatrically ill adults and medically ill children and young adults.
Synapsin II (formerly known as protein III) is a synaptic vesicle-associated neuronal phosphoprotein that may be involved in the regulation of neurotransmitter release. Synapsin II was studied inExpand
  • 23